II. Indications
- Routine Scheduled Vaccine for all teens in U.S. (Menactra)
- All 12 year olds
- First dose
- All 16 year olds
- Booster, second dose for those who received a dose prior to age 16 years
- Catch-up any 16 year olds if not immunized (single dose)
- All 12 year olds
- High risk Patients (see risk factors below)
- See CDC guidelines (vary by population and Vaccine)
III. Indications: Risk Factors and age 55 years and younger
- Underlying medical condition
- Anatomic Asplenia or Functional Asplenia (e.g. Sickle Cell Anemia)
- Terminal complement deficiency
- Properdin deficiency
- Human Immunodeficiency Virus (HIV)
- Complement Inhibitor (eculizumab, ravulizumab)
- Close living areas
- College students in dormitories
- Military recruits
- Travel to endemic areas
- Sub-Saharan Africa
- Himalayas
- Saudi Arabia (especially Mecca)
IV. Contraindications
- Age over 55 years
- Use Menomune (Quadrivalent Meningococcal Polysaccharide Vaccine) instead
V. Preparations
- Primary preparations
- Menactra (MenACWY-D)
- Approved for age over 9 months
- Menveo (MenACWY-CRM)
- Approved for age over 2 months
- Menactra (MenACWY-D)
- Other preparations
- Menhibrix (Hib-MenCY, high risk infants only who are also due for Hib Vaccine)
VI. Mechanism
- Tetravalent Meningococcal Conjugate Vaccine
- Covers strains A, C, W-135, Y (same as Menomune)
- Serotypes C and Y each account for a third of U.S. meningococcal cases
- Serotype B accounts for another third (but not included in the Vaccine, see below)
- Serotypes A and W are strains seen worldwide
- Does not cover serotype B (same as Menomune)
- Preferred in most cases over MPSV4 (higher immunogenicity)
- Conjugate Vaccine with Diphtheria protein
- Cost: $100 (similar to Menomune)
- Storage: 35 to 46 F (2 to 8 C, same as Menomune)
VII. Dosing: Menactra
- Administer 0.5 ml IM
-
General dosing protocol if under age 16 years at time of first dose
- Booster dose before entering high risk environment (e.g. college dormitory, travel to endemic area, lab workers)
-
General dosing protocol if over age 16 years at time of first dose
- Single dose with no booster recommended
- Indications for a two dose series (with 2 month interval) and no further boosters
- Human Immunodeficiency Virus infection
- Indications for a two dose series (with 2 month interval) and future boosters every 5 years
- No functioning Spleen or
- Persistent complement deficiency
- Miscellaneous points
VIII. Efficacy
IX. Precautions: Safety
- Approved for ages 11 to 55 years
- May also be used at 2-10 years of age due to risk factors or travel
- No longer associated with Guillain-Barre (despite early reports)
- Vaccine has no preservative (single use vial)
- Safe in Human Immunodeficiency Virus (HIV)
X. Adverse effects
XI. Resources
- CDC Immunization Schedules (last accessed 10/28/2020)
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI) | Any vaccine derived from Neisseria meningitidis whether in whole-cell or acellular form used for prophylaxis against meningitis. |
Definition (MSH) | Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS. |
Concepts | Pharmacologic Substance (T121) , Immunologic Factor (T129) |
MSH | D022401 |
SnomedCT | 424891007, 423531006, 69728004, 396430005 |
English | Meningococcus vaccine (substance), Meningococcus vaccine, Meningococcus vaccine (product), Meningococcal vaccine, meningococcal vaccine (medication), meningococcal vaccine, Meningococcal Vaccines [Chemical/Ingredient], Meningococcal Vaccine,Meningococcal Vaccine, meningococcus vaccine, meningococcal vaccines, Meningococcal Vaccine, Meningococcal Vaccines, Vaccine, Meningococcal, Vaccines, Meningococcal, Meningococcal vaccines |
Swedish | Meningokockvacciner |
Spanish | vacuna antimeningocócica, vacuna antimeningocócica (producto), vacuna antimeningocócica (sustancia), Vacunas Meningococicas |
Czech | meningokokové vakcíny |
Finnish | Meningokokkirokotteet |
Russian | VAKTSINY MENINGOKOKKOVYE, MENINGOKOKKOVYE VAKTSINY, ВАКЦИНЫ МЕНИНГОКОККОВЫЕ, МЕНИНГОКОККОВЫЕ ВАКЦИНЫ |
Japanese | ワクチン-髄膜炎, 多糖類ワクチン-髄膜炎, 髄膜炎多糖類ワクチン, 髄膜炎ワクチン |
Italian | Vaccino meningococcico, Vaccini meningococcici |
Polish | Szczepionki przeciw meningokokom, Szczepionki przeciw zakażeniu meningokokami |
Portuguese | Vacinas contra Meningococos, Vacinas contra Neisseria meningitidis, Vacinas Meningocócicas |
French | Vaccins antiméningococciques, Vaccin antiméningococcique, Vaccin méningococcique, Vaccins méningococciques |
German | Menigokokkenvakzine |
Ontology: Menactra (C1567129)
Concepts | Immunologic Factor (T129) , Pharmacologic Substance (T121) |
MSH | D022401 |
English | Menactra |